User:Vineela Parvathaneni/sandbox

Dr. Vineela Parvathaneni (Born 20 Aug 1988 in Guntur, India) is an Indian Scientist works at Thermo Fisher Scientific, Drug Product - North America of the PSG) and a researcher in exploration of drug repurposing, Novel Drug Delivery systems, Cancer Treatment. She received her PhD in Pharmaceutical Sciences (Industrial Pharmacy) from St. John's University (New York City) USA, M. Pharm in Pharmaceutical Sciences from Chalapathi Institute of Pharmaceutical Sciences and B. Pharm from Sri Padmavathi Mahila Viswavidyalayam, India.

Vineela worked on developing novel drug discovery and delivery strategies with primary focus on inventing new treatment regimens for diseases of the respiratory system including lung cancer, mesothelioma and breast cancer. Vineela also investigated the possibility of repurposing an anti-fibrotic drug molecule, pirfenidone for lung cancer treatment by use of lipid-based delivery systems. She was not only successful in developing lipid-based formulations for pirfenidone but also successfully learnt, executed all cell based and molecular biology experiments. In addition, She was also instrumental in setting up many research equipment including high pressure homogenization (HPH), which is one of the few equipment capable of being scaled up in pharmaceutical industry settings. She also developed and executed Design of Experiments (DoE) based formulation development approach for repurposing amodiaquine, an anti-malarial drug, for lung cancer treatment. Vineela has published many research/review articles in high impact peer- reviewed scientific journals like Drug Discovery Today, Materials Science and Engineering C, International Journal of Biological Macromolecules etc. and her publications are cited worldwide. .

Contribution to Science
1. Exploring New Indications for Old Drugs Through Drug Repurposing:

Vineela worked on several drug molecules approved for various indications to identify their efficacy in multiple diseases. She published a review article which focusses on significance of drug repurposing and different strategies available for successful drug repurposing. In many of her projects, Vineela carried out systematic development of formulations while focusing on tackling the existing issues related to development of new therapies by repurposing FDA approved anti-fibrotic drug. To name few, anti-viral and anti-malarial drugs were explored for its efficacy in treating NSCLC through encapsulating in nanoparticles.

''a. Parvathaneni V, Kulkarni NS, Muth A, Gupta V (2019). Drug repurposing: a promising tool to accelerate and the drug discovery process. Drug Discovery Today. ''

''b. Parvathaneni V, Goyal M, Gupta V (2019). Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). ''

''c. Parvathaneni V, Shukla SK, Farrales PT, Kunda NK, Muth A, Gupta V (2020). Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment – Pharmaceutics 12(3):206 ''

''d. Bhuvaneshwar Vaidya, Nishant S Kulkarni, Snehal K Shukla, Vineela Parvathaneni et al (2020). Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: repurposing quinacrine for lung cancer therapeutics.  e. Nishant S Kulkarni, Bhuvaneshwar Vaidya, Vineela Parvathaneni et al (2020). Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation. ''

''f. Parvathaneni V, Gupta V. Repurposing an Antimalarial Drug for Efficacy in Diverse Breast Cancer Subtypes. 2019 AAPS PharmSci 360, San Antonio, TX. ''

2. Development of Novel Delivery Systems to Treat Pulmonary Disorders:

Vineela has investigated on the development of novel drug delivery systems such as liposomes, polymeric and solid lipid nanoparticles either as primary projects or in collaboration with her colleagues. Vineela attained a vast experience in trouble shooting the formulation challenges and also involved in the exploration of inorganic quantum dots' importance as theranostic tools in NSCLC therapy.

''a. Kulkarni NS, Parvathaneni V, Shukla SK,et al (2019). Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. European Journal of Pharmaceutical Sciences 133:145-159. ''

''b. Vaidya B, Parvathaneni V, Kulkarni NS, et al (2018). Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. International Journal of Biological Macromolecules 122:338-347. ''

''c. Xuechun Wang, Vineela Parvathaneni, et al (2020). Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer. ''

''d. Snehal K Shukla, Nishant S Kulkarni, Pamela Farrales, Dipti D Kanabar, Vineela Parvathaneni, et al (2020). Sorafenib loaded inhalable polymeric nanocarriers against non-small cell lung cancer. ''

''e. Snehal K Shukla, Amanda Chan, Vineela Parvathaneni, et al (2020). Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma–A rare thoracic cancer. ''

3. Development of Scalable and Inhalable Drug Delivery Systems:

Vineela has extensively involved in research to develop delivery systems which can be scaled up to an industrial scale being scalable. While nanoparticles being the most efficient systems in delivering therapeutics, there are encountering several challenges related to their scale-up. Hence, Vineela used a scalable high-pressure homogenization (HPH) approach to formulate inhalable polymeric nanoparticles. Due to the feasibility to change surface properties through attaching targeting ligands, potential targeting and specificity can be achieved.

''a. Parvathaneni V, Kulkarni NS, Chauhan G, Shukla SK, Elbatanony R, Patel BI, Kunda NK, Muth A, Gupta V (2020). Development of Pharmaceutically Scalable Inhaled Anti-cancer Nanotherapy – Repurposing Amodiaquine for Non-Small Cell Lung Cancer (NSCLC) – Materials Science & Engineering C 115:111139. ''

''b. Parvathaneni V, Gupta V. Development and Evaluation of Transferrin Conjugated Amodiaquine Nanoparticles - Non-Small Cell Lung Cancer (NSCLC) Targeted Therapy. 2020 AAPS PharmSci 360. ''

Awards and honors
Vineela's national and international awards include:
 * AAiPS Graduate Award 2020 - American Association of Indian Pharmaceutical Scientists.
 * Doctoral Research Fellowship Award 2020-2021 - St John’s University.
 * Dr. Charles I. Jarowski Legacy Award (Outstanding Publication and Academic record) 2019 - St John’s University
 * AAPS Best Abstract Award 2019 - American Association of Pharmaceutical Scientists.
 * ATS Student Scholarship 2019 - American Thoracic Society.
 * AAPS Student Chapter Award 2019 - American Association of Pharmaceutical Scientists.
 * NJPhAST Graduate Scholarship Award 2018 - New Jersey Pharmaceutical Association for Science and Technology (NJPhAST).

Book Chapters
1. “Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis” in Molecular and Translational Medicine Book Series.

2. “Current Status and Perspectives in Mucosal Drug Delivery of Nanotherapeutic Systems” in AAPS Advances in the Pharmaceutical Sciences Series.

3. “Evaluation of 3D Cell Culture Models for Efficacy Determination of Anticancer Therapeutics and Nanoparticles” in Drug Delivery with Targeted Nanoparticles In Vitro and In Vivo Evaluation Methods.

Journal Associations as Peer Reviewer

 * Scientific Reports.
 * Artificial Cells, Nanomedice and Biotechnology.
 * European Journal of Pharmaceutical Sciences
 * Plos One
 * Anti-Cancer Drugs
 * Drug Testing and Analysis.